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CORONAVIRUS
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INTRODUCTION

Infection with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Acute
respiratory failure occurs in a subset of patients with COVID-19
(1–3). Respiratory failure has occurred in as many as 8% of individuals
testing positive for infection in the Lombardy region of Italy (4).
Understanding the etiology of respiratory failure in patients with
COVID-19 is critical for determining the best management strategies
and pharmacologic targets for treatment. Current management of
acute respiratory failure in COVID-19 consists of optimized supportive care (5, 6), primarily through oxygen administration and consideration of endotracheal intubation and mechanical ventilation in the
appropriate context (7). Recent evidence published in the RECOVERY
(Randomized Evaluation of COVID-19 Therapy) trial (8) suggests
that the administration of high dose steroids in a small subgroup of
critically ill patients may reduce mortality.
Cytokine storm syndrome (CSS) has been proposed as underlying
the etiology of respiratory failure in patients with COVID-19 (9).
This model suggests that respiratory failure is related to significant
proinflammatory cytokine expression that leads to inflammatory
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cell recruitment and tissue damage in the lung. Most of the data
supporting this hypothesis in COVID-19 come from an early paper
that observed high levels of the cytokines interleukin-2 (IL-2), IL-7,
IL-10, granulocyte colony-stimulating factor (G-CSF), Interferon
-induced protein 10 (IP-10), monocyte chemoattractant protein 1
(MCP1), macrophage inflammatory protein–1 (MIP-1), and
tumor necrosis factor  (TNF) in a small cohort of patients with
COVID-19 being cared for in the intensive care unit (ICU). The level
of these cytokines was increased in the ICU patients compared
with a group of patients with COVID-19 that did not require care in
the ICU (3). The CSS hypothesis for respiratory failure in COVID-19
has recently been challenged, as others have more closely examined
data from early studies of cytokine expression in patients with
COVID-19 (10). CSS, while not specifically defined, is clearly
observed in conditions such as hemophagocytic lymphohistiocytosis (11), severe cases of avian influenza (12), Castleman disease (13), and in the cytokine release syndrome observed in a subset of
patients following chimeric antigen receptor T cell therapy for
malignancy (14). In these cases of true CSS, circulating blood levels
of multiple cytokines are elevated usually more than 10-fold above
baseline levels and generally demonstrate skewing toward a T helper
1 (TH1)–type cytokine response profile suggestive of an increased T
cell response. Reported cytokine expression levels in studies of
patients with COVID-19, although increased in individuals with
severe illness, are elevated only marginally, less than twofold above
those observed in noncritically ill subjects (3). Very few studies compare COVID-19 inflammatory responses to those observed in other
viral illnesses that lead to acute respiratory failure, such as influenza (15).
There has been significant interest in modulating the systemic
immune response in an effort to prevent or treat respiratory failure
in patients with COVID-19 (2, 8, 16–18). More than 100 clinical
trials are currently registered at clinicaltrials.gov to evaluate the
1 of 17
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We pursued a study of immune responses in coronavirus disease 2019 (COVID-19) and influenza patients. Compared
to patients with influenza, patients with COVID-19 exhibited largely equivalent lymphocyte counts, fewer monocytes, and lower surface human leukocyte antigen (HLA)–class II expression on selected monocyte populations.
Furthermore, decreased HLA-DR on intermediate monocytes predicted severe COVID-19 disease. In contrast
to prevailing assumptions, very few (7 of 168) patients with COVID-19 exhibited cytokine profiles indicative of
cytokine storm syndrome. After controlling for multiple factors including age and sample time point, patients
with COVID-19 exhibited lower cytokine levels than patients with influenza. Up-regulation of IL-6, G-CSF, IL-1RA,
and MCP1 predicted death in patients with COVID-19 but were not statistically higher than patients with influenza.
Single-cell transcriptional profiling revealed profound suppression of interferon signaling among patients with
COVID-19. When considered across the spectrum of peripheral immune profiles, patients with COVID-19 are less
inflamed than patients with influenza.
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RESULTS

Demographic and clinical characteristics
We enrolled a total of 79 symptomatic subjects in the initial (primary) cohort who tested positive for SARS-CoV-2 RNA using a Food
and Drug Administration–approved clinical polymerase chain reaction (PCR) test. Our comparison group consisted of 26 symptomatic seasonal influenza subjects recruited during the period of
15 months immediately preceding the outbreak of COVID-19 in the
Saint Louis region, all of whom tested positive for influenza A or B
via a clinical PCR test obtained during their clinical care. COVID-19
subjects were, on average, 19 years older than influenza subjects and
29 years older than control subjects (Table 1). A greater number of
COVID-19 subjects required hospitalization, ICU admission, and
mechanical ventilation than influenza subjects, but this was not significantly different after controlling for demographic factors and
other clinical characteristics. Twenty-seven percent of the COVID-19
subjects died during their hospitalization compared with 8% of influenza subjects enrolled. Many subjects in both influenza and
COVID-19 groups exhibited comorbidities that increased their risk
for severe disease, including diabetes and chronic lung disease; however, there were no significant differences between the COVID-19
and influenza subjects in any analyzed comorbidity (Table 1). Both
the COVID-19 and influenza cohorts included subjects with moderate
disease, as defined by individuals with symptomatic illness requiring
evaluation in the hospital, and severe disease, as defined by individuals
requiring mechanical ventilation for acute respiratory failure or who
ultimately died due to their illness.
Evaluation of circulating immune cells
Using peripheral blood mononuclear cells (PBMCs) from 15 healthy,
23 influenza-infected, and 22 COVID-19–infected subjects, we examined the composition and activation of circulating leukocytes with
flow cytometry. We used multivariate linear regression with subject
age, sex, ethnicity, symptom duration at study enrollment, and all
Mudd et al., Sci. Adv. 2020; 6 : eabe3024
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comorbidities as covariates to explore immune cell dynamics as a
function of condition while statistically controlling for demographic
and other clinical differences across the patient groups. We initially
characterized circulating immune cells by quantifying the absolute
number of CD4+ and CD8+ T lymphocytes and CD19+ B cells.
COVID-19 and influenza subjects exhibited trends of decreased
B cells and significant reductions in both T cell subsets, which generally constitute most of the circulating PBMCs in healthy controls
(Fig. 1A and fig. S1A). In contrast, COVID-19 subjects had significantly more circulating early antibody-secreting B cell plasmablasts
than controls (Fig. 1B). Circulating activated CD4+ and CD8+ cells
were equivalent across all groups (Fig. 1B). However, when compared with either influenza or control subjects, COVID-19 subjects
exhibited significantly reduced numbers of circulating monocytes,
including all three common classifications of human monocytes
(classical, intermediate, and nonclassical; Fig. 1C and fig S1B).
Given the pronounced variation in monocyte abundance across
patient conditions, we also measured major histocompatibility complex class II expression on the surface of monocytes to gauge monocyte
activation. We noted that COVID-19 subjects had reduced abundances of HLA-DR on the surface of all classes of monocyte when
compared with influenza subjects or controls, although only intermediate monocytes reached statistical significance after controlling
for covariate effects (Fig. 1D). In addition, patients with COVID-19
exhibited significantly less surface HLA-DR on CD8+ T cells than
patients with influenza and trends toward less HLA-DR on CD4+
T cells in comparison to both patients with influenza and healthy controls (Fig. 1E). Once again using multivariate linear regression, we
next assessed potential differences in HLA-DR abundance between
patients with moderate illness and those with severe illness, defined
as those who required intubation and mechanical ventilation or
who ultimately expired as a result of their illness. Although there
were no associations with severity in HLA-DR abundance among
lymphocyte populations, we found that, compared to moderately ill
patients, the severest patients exhibited substantially less HLA-DR
on intermediate and nonclassical monocytes (fig. S1, C and D).
Cytokine associations with disease
From this primary cohort, plasma cytokine levels were measured from
79 patients with SARS-CoV-2 (COVID-19) infection, 26 patients with
confirmed influenza virus infection, and 8 healthy controls. Among
the patients with COVID-19, two response profiles were immediately
apparent, with 3 of 79 patient samples exhibiting obviously distinct
cytokine profiles in principal components analysis (PCA; Fig. 2A).
These samples were characterized by cytokine levels of >2 SDs from
the mean for more than 17 of the 35 cytokines measured (range: 49
to 89%), encompassing broad and unfocused immune responses
characteristic of classic cytokine storm (see outliers; fig. S2). Cytokine storms in other conditions have been defined by extreme deviations
in the levels of a broad array of cytokines rather than just moderate
elevations in targeted pathways (19). SDs from the mean ranged from
2 to 10.5 among these CSS subjects, with outlier values ranging from
0.8 to 2 orders of magnitude higher than the mean for each of the
measured cytokines. Patients with CSS were all African American, one
female (89 years) with no noted comorbidities, one female (62 years)
with diabetes mellitus, and a male (47 years) with diabetes mellitus
and preexisting chronic pulmonary disease (table S1). All three
patients with CSS were admitted to the ICU, required intubation
and mechanical ventilation, and ultimately expired. In subsequent
2 of 17

Downloaded from http://advances.sciencemag.org/ on January 11, 2021

efficacy of inflammatory cytokine blocking medications or interventions such as cytokine filtration as potential treatments for
respiratory failure in patients with COVID-19. The RECOVERY dexamethasone study suggests a mortality benefit for immunomodulation
therapy in a subset of critically ill patients with COVID-19 (8). A
thorough understanding of the underlying inflammatory environment in patients with COVID-19 is required to carefully select patients for these studies of potential treatments, especially in light of
the increased (although not statistically significant) rate of death
observed in patients without an oxygen requirement who were given dexamethasone in the RECOVERY trial.
To understand the relationship between inflammatory host responses and the respiratory failure observed in patients with COVID-19,
we undertook a comparative investigation of inflammatory responses
in a cohort of influenza patients with severe illness collected during
2019–2020, which allowed us to characterize the immune response
in patients with severe COVID-19 specifically in the context of the
more widely studied immune responses seen in respiratory disease
caused by influenza. These comparisons reveal that, despite prevailing
assumptions in the literature, CSS is relatively rare among moderate
and severe COVID-19 infections; rather, most patients with COVID-19
in the current study exhibited suppressed immune profiles relative
to the patterns observed among influenza-infected patients.

SCIENCE ADVANCES | RESEARCH ARTICLE
Table 1. Demographics and clinical characteristics of primary cohort. Statistical analyses of primary cohort demographics include comparisons between
COVID-19 and healthy groups for age, sex, and ethnicity using a multinomial logistic regression that includes the variation from influenza-infected individuals.
Comparisons between COVID-19 and influenza groups were assessed using a multivariate logistic regression that included demographic and clinical variables
but without including variation from the healthy group, as clinical characteristics were irrelevant to healthy controls. Results are reported as the corresponding
P value and, when significant, include the odds ratio (OR). COVID-19 serves as the reference condition in all analyses, “African American” serves as the reference
for ethnicity comparisons, and the negative indication serves as the reference for all categorical clinical characteristics. A significant OR > 1 indicates a positive
association between the comparator group and the variable (e.g., healthy individuals were more likely to self-identify as Caucasian than patients with
SARS-CoV-2), whereas a significant OR < 1 indicates a negative association (e.g., influenza-infected patients were likely to be younger than patients with
SARS-CoV-2). The “immunocompromised” comorbidity was not included in the logistic regression due to complete separation across conditions and was
instead tested using Fisher’s exact test. P values were adjusted for multiple testing by controlling the false discovery rate. SD denotes standard deviation, and
IQR denotes interquartile range. N.S., not significant.
SARS-CoV-2
(n = 79)

Healthy
control
(n = 16)

Influenza
(n = 26)

COVID-19–healthy
comparison

COVID-19–
influenza
comparison

61 ± 15
(25–89)

32 ± 7 (22–49)

42 ± 17 (18–89)

P < 0.001, OR = 0.85

P = 0.007,
OR = 0.93

44% (35/44)

50% (8/8)

58% (15/26)

P = 1, N.S.

P = 1, N.S.

African American

80% (63/79)

44% (7/16)

65% (17/26)

–

–

White

18% (14/79)

56% (9/16)

27% (7/26)

P < 0.05, OR = 9.59

P = 0.718, N.S.

Other

<3% (2/79)

0% (0/16)

8% (2/26)

–

P = 1, N.S.

Demographics
Means ± SD (range) age, in years
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Female
Ethnicity

Clinical characteristics
Mean (IQR) symptom duration at
study enrollment, in days

6.4 (3–9)

4.1 (2–7)

P = 0.229, N.S.

Hospital admission

90% (71/79)

58% (15/26)

P = 0.229, N.S.

ICU admission

56% (44/79)

35% (9/26)

P = 0.285, N.S.

Intubation and mechanical
ventilation

44% (35/79)

27% (7/26)

P = 0.285, N.S.

In-hospital death

30% (24/79)

8% (2/26)

P = 0.234, N.S.

Comorbidities
Immunocompromised

6% (5/79)

0% (0/26)

P = 0.33, N.S.

Chronic lung disease

34% (27/79)

42% (11/26)

P = 0.682, N.S.

Chronic heart failure

13% (10/79)

23% (6/26)

P = 0.101, N.S.

5% (4/79)

8% (2/26)

P = 0.582, N.S.

43% (34/79)

27% (7/26)

P = 0.628, N.S.

6% (5/79)

8% (2/26)

P = 0.234, N.S.

End-stage renal failure
Diabetes mellitus
Active cancer

analyses, these three patients were visualized and analyzed as a
separate CSS group unless otherwise noted. Among the remaining
76 COVID-19 samples from this primary cohort, patients often exhibited values outside 1.5 interquartile ranges for individual cytokines (fig. S3), suggestive of activation of specific pathways; however,
the vast majority of each patient’s individual cytokine levels were well
within the majority of the observed variation, which does not support
the broad dysregulation of cytokines expected in a CSS phenotype.
We and others have previously shown that many cytokines are
often correlated with demographic and environmental factors (e.g.,
age and prior herpesvirus exposure) (20). To assess cytokine differences across groups while controlling for these potentially confounding factors, including the significant differences in age observed within
our cohort, we generated estimated marginal means from linear regression models that incorporated age, sex, ethnicity, days since symptom onset at enrollment, and all reported comorbidities as covariates.
In comparison to healthy controls, both influenza and COVID-19
Mudd et al., Sci. Adv. 2020; 6 : eabe3024
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subjects exhibited elevated levels of a number of cytokines. Among
patients with COVID-19, IP-10, IL-8, MCP1, HGF (hepatocyte
growth factor) and MIP-1 were significantly up-regulated compared
to healthy controls, in addition to apparent (but not statistically significant) trends for increases in MIG (monokine induced by interferon
gamma), granulocyte-macrophage CSF (GM-CSF), IL-1RA, IL-2, IL-17f,
and IL-6 (Fig. 2B and fig. S3). In comparison to healthy controls,
influenza-infected patients likewise exhibited significant up-regulation
of all of cytokines up-regulated among patients with COVID-19,
but influenza-infected patients also exhibited significantly greater
abundances (compared to COVID-19–infected patients) of a number
of cytokines with known inflammatory and immunomodulatory
roles, including MIG, IL-1RA, IL-2R, IL-2, IL-17f, and IL-12 (fig. S3).
To elucidate the unique ways in which COVID-19 modulates
cytokine profiles, we focused the majority of cytokine analyses on
comparisons between the COVID-19 and influenza groups. Direct
comparisons between infected groups revealed that the dominant
3 of 17
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Fig. 1. Evaluation of circulating lymphocyte and monocyte subpopulations in select healthy controls (N = 15), acute influenza-infected subjects (N = 23), and
acute SARS-CoV-2–infected subjects (N = 22). Absolute numbers of (A) B cells, CD8+ T cells, and CD4+ T cells; (B) circulating B cell plasmablasts, activated CD8+ T cells,
and activated CD4+ T cells; and (C) classical, intermediate, and nonclassical monocytes were quantified by flow cytometry. Surface expression of the major histocompatibility complex class 2 molecule, HLA-DR, on the surface of the indicated subpopulations of circulating monocytes (D) and lymphocytes (E) as measured by geometric
mean fluorescence intensity (MFI) using flow cytometry. Presented P values are from pairwise comparisons of estimated marginal means of linear regression models that
adjust for ethnicity, sex, age, and all comorbidities (immunocompromised, end-stage renal disease, chronic lung disease, chronic heart failure, and diabetes mellitus). P
values were adjusted for multiple comparisons using Tukey’s method. For comparisons between COVID-19 and influenza, the models also include days of symptom
duration at study enrollment as a covariate. In each case, raw values are plotted on the log10 scale.
Mudd et al., Sci. Adv. 2020; 6 : eabe3024
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Fig. 2. Selective cytokine up-regulation in patients with COVID-19 from the primary cohort. (A) Top: PCA of 35 cytokines measured in COVID-19 subjects from the
primary cohort. Red circles: patients with CSS; green dots: all other subjects. Samples with missing cytokine data were excluded. Bottom: corresponding PCA loadings
indicating effects of each cytokine. (B) Relative cytokine abundance plot, with each cytokine normalized to the respective median cytokine level in influenza subjects. The
normalized median cytokine level in influenza patients (1.0) is represented by the vertical blue line. Bar graphs represent the normalized median COVID-19 cytokine level
relative to the normalized median influenza cytokine level. Light red bars: cytokine levels lower in COVID-19 than influenza patients (normalized median < 1, n = 28); dark
red bars: cytokines levels greater in patients with COVID-19 than in patients with influenza (normalized median > 1, n = 7). (C) Box plots show cytokine concentrations in
healthy, influenza, COVID-19, and CSS subjects, with raw values plotted on the log10 scale. P values are from estimated marginal means (EMM) comparisons, averaging
over all demographic and clinical factors included as covariates and adjusted for multiple comparisons. To the right of each box plot are EMM plots for the influenza–
COVID-19 comparison. Black dot: estimated marginal mean for the log10 concentration of the cytokine, averaged over the levels of all other covariates; blue shading:
corresponding 95% confidence interval; red arrows: SE in one direction, with overlapping SE arrows indicating no significant difference between the EMM of a given cytokine in influenza subjects versus COVID-19 subjects.
Mudd et al., Sci. Adv. 2020; 6 : eabe3024
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Validation of COVID-19 cytokine patterns in an additional
SARS-CoV-2 cohort
To validate the cytokine patterns observed among COVID-19,
influenza, and healthy control groups in our primary cohort, we
enrolled a follow-up cohort that consisted of the next 89 consecutive confirmed patients with COVID-19 enrolled into the ongoing
prospective observational study (Table 2). Cytokine data from these
patients were collected and analyzed as described for the primary
cohort. Among the 89 patients in the validation cohort, four exhibited marked variation in their cytokine profiles (Fig. 3A, red circles)
that, although not as extreme as those in the primary cohort, were
consistent with a CSS phenotype (fig. S5). These samples were characterized by cytokine levels of >2 SDs from the mean for more than
9 of the 35 cytokines measured (range: 26 to 49%). Two of these
patients self-identified as African American (59-year-old female,
71-year-old male), one as “other” (41-year-old male), and one as white
(64-year-old male). Both African-American patients with CSS had
been previously diagnosed with diabetes mellitus, and the 59-year-old
female also had been diagnosed with chronic heart failure and chronic
pulmonary disease and was immunosuppressed. The other patients
with CSS had no listed comorbidities. The 64-year-old male patient
was admitted to the ICU, required intubation and mechanical
ventilation, and ultimately expired. None of the other three patients
with CSS were intubated, and all ultimately survived. In contrast to
these CSS profiles, another subset of three patients exhibited a unique
profile with a classic TH22 signature (Fig. 3A, blue circles), consisting
of production of high levels of IL-22, GM-CSF, and IL-13 without
high levels of IL-17. All patients with a TH22 signature were female
African Americans (aged 19, 26, and 71) with no listed comorbidities.
None required intubation, and all survived. Although samples
exhibiting the TH22 signature are plotted separately for visual comparison, they were considered to represent regulated cytokine responses
and were therefore included as COVID-19 validation samples in all
statistical analyses.
Mudd et al., Sci. Adv. 2020; 6 : eabe3024
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Comparison of cytokine measures from the validation cohort to
the original healthy controls and patients with influenza were largely
consistent with those observed in the primary cohort. In addition to
significantly higher levels of IP-10, IL-8, HGF, and MIP-1 observed
among patients with COVID-19 from the primary cohort in comparison to healthy controls, the validation cohort also exhibited significantly greater levels of IL-12, epidermal growth factor (EGF),
and IL-2 (fig. S6), two of which were consistent with trends observed in the primary cohort analyses (fig. S3).
In comparison to influenza-infected subjects, the COVID-19
subjects in the validation cohort also exhibited many of the same
patterns observed within the primary COVID-19 cohort with the
single exception of MIP-1 (P = 0.14), which may have differed due
to variations in the assay’s lower limits of detection. In addition, the
validation COVID-19 cohort in comparison to influenza-infected subjects exhibited significantly lower levels of IL-1, IL-4, IP-10, TNF,
IL-1, IL-17f, fibroblast growth factor (FGF), and eotaxin (Fig. 3, B and C,
and figs. S6 and S7), several of which were consistent with nonsignificant
trends observed in the primary cohort analyses (figs. S3 and S4). We
again detected no significant difference in either IL-6 or IL-8 between
influenza-infected and COVID-19–infected patients after controlling
for demographic and clinical covariates (Fig. 3D). Overall, these data
validated our observation in the primary cohort that many cytokines are down-regulated in patients with COVID-19 compared to
influenza-infected patients, suggesting that overall higher inflammation is foremost predictive of influenza infection and that a
defining feature of COVID-19 disease is generally reduced inflammation compared to influenza; aside from the 4% of patients with
extreme cytokine dysregulation (i.e., CSS), COVID-19 subjects were
not characterized by overall high levels of cytokines but rather exhibited a selective pattern of inflammation in which only a subset of
inflammatory cytokines were up-regulated, and most were down-
regulated when compared with seasonal influenza patients.
Cross-cohort comparisons and integrated cytokine analyses
Comparison of the validation cohort to the COVID-19 group from
the primary cohort revealed no significant differences in demographics or comorbidities, save for a significant reduction in preexisting chronic lung disease (16% in the validation cohort compared
to 34% in the original cohort; Table 2). Of the other clinical characteristics considered, the validation cohort was significantly less likely to receive mechanical ventilation (27% compared to 44%). We
hypothesize that this difference reflects the evolution of treatment
approaches over time rather than an underlying difference in the
patient population, as the difference in ventilation rates was significant after controlling for differences in comorbidities, and there
was no significant difference in death rates between the cohorts.
Furthermore, written guidance to the clinical staff at the study institutions over the course of the first weeks of the pandemic reflected
a nationwide transition from initial recommendations for early and
aggressive intubation of patients with COVID-19 with relatively
moderate hypoxia to later written guidance that focused on maximizing
oxygen delivery strategies before intubation using more traditional
approaches to acute respiratory failure. Although we found a significant negative association between the week of enrollment and the
percentage of patients intubated (fig. S8A), we observed the opposite relationship between the week of enrollment and the percentage
of patients who survived infection (fig. S8B). These correlations
suggest that aggressive early intubation strategies may have been
6 of 17
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response profile among patients with COVID-19 consisted of more
selective cytokine up-regulation, with a relative bias toward lower
inflammation when compared to patients with influenza (Fig. 2,
B and C). Among all subjects, we found that for 28 of 35 cytokines,
patients with COVID-19 had lower median cytokine levels, although
not all were statistically significant (Fig. 2B and fig. S3). Among the
statistically significant reduced cytokines exhibited by patients with
COVID-19 compared to influenza patients were interferon- (IFN-),
MIG, IL-1RA, IL-2R, G-CSF, IL-17a, IL-9, and MIP-1. Upon visual
inspection of the raw data, both IL-6 and IL-8 appeared to be greater
among COVID-19 than influenza-infected patients, but the estimated
marginal means of neither cytokine was significantly different after
controlling for covariates (Fig. 2C and figs. S3 and S4), particularly
the effects of age, sex, and preexisting pulmonary disease. This finding
is particularly relevant in the ongoing discussion of COVID-19 cytokine profiles: Although some cytokines seem to be higher among
patients with COVID-19, those differences are potentially inflated
by other underlying demographic and clinical differences. For instance, hospitalized patients with COVID-19 are generally older
[Table 1; (21)], and many baseline cytokine levels increase with age
(22, 23). When accounting for these and other confounding factors,
the data indicated that most patients with COVID-19 did not have
an inflammatory phenotype as profound as patients with influenza,
with certain targeted exceptions.

SCIENCE ADVANCES | RESEARCH ARTICLE
Table 2. Demographics and clinical characteristics of validation cohort with comparisons to primary cohort subsets. Statistical analyses of validation
cohort demographics include comparisons between validation and healthy groups for age, sex, and ethnicity using a multinomial logistic regression that
includes the variation from influenza-infected individuals. Comparisons between the validation cohort and both patient groups from the primary cohort
(COVID-19 and influenza) were assessed using a multivariate logistic regression that included demographic and clinical variables. Results are reported as the
corresponding P value and, when significant, include the OR. The validation cohort serves as the reference condition in all analyses, African American serves as
the reference for ethnicity comparisons, and the negative indication serves as the reference for all categorical clinical characteristics. A significant OR > 1
indicates a positive association between the comparator group and the variable (e.g., patients with COVID-19 from the primary cohort were more likely to be
intubated than validation cohort patients with COVID-19), whereas a significant OR < 1 indicates a negative association (e.g., healthy controls were likely to be
younger than validation cohort patients). P values were adjusted for multiple testing by controlling the false discovery rate. SD denotes standard deviation, and
IQR denotes interquartile range. The “immunocompromised” comorbidity was not included in the validation-influenza comparison logistic regression due to
complete separation across groups and was instead tested using Fisher’s exact test.
SARS-CoV-2 validation
(n = 89)

Validation-primary
COVID-19 comparison

Validation-healthy
comparison

Validation-influenza
comparison

61 ± 17 (19–92)

P = 1, N.S.

P < 0.001, OR = 0.87

P = 0.041, OR = 0.93

39% (35/89)

P = 1, N.S.

P = 1, N.S.

P = 1, N.S.

Demographics
Means ± SD (range) age,
in years
Female
African American

74% (66/89)

–

–

–

White

25% (22/89)

P = 1, N.S.

P = 0.069, N.S.

P = 1, N.S.

Other

1% (1/89)

P = 1, N.S.

–

P = 1, N.S.

Mean (IQR) body mass
index

28.6 (24–33)

–

–

Mean (IQR) symptom
duration at study
enrollment, in days

7.5 (2–9)

P = 0.958, N.S.

P = 0.635, N.S.

Hospital admission

94% (84/89)

P = 0.958, N.S.

P = 0.043, OR = 0.046

ICU admission

48% (43/89)

P = 0.10, N.S.

P = 1, N.S.

Intubation and mechanical
ventilation

27% (24/89)

P < 0.001, OR = 19.03

P = 0.893, N.S.

In-hospital death

17% (15/89)

P = 0.509, N.S.

P = 1, N.S.

8% (7/89)

P = 1, N.S.

P = 0.347, N.S.

Chronic lung disease

16% (14/89)

P = 0.017, OR = 5.9

P = 0.049, OR = 11.69

Chronic heart failure

15% (13/89)

P = 1, N.S.

P = 0.817, N.S.

2% (2/89)

P = 1, N.S.

P = 1, N.S.
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Ethnicity

Clinical characteristics

Comorbidities
Immunocompromised

End-stage renal failure
Diabetes mellitus
Active cancer

44% (39/89)

P = 1, N.S.

P = 1, N.S.

3% (3/89)

P = 0.893, N.S.

P = 0.387, N.S.

unwarranted or even harmful, but further study is required. An
alternative hypothesis is that disease severity somehow naturally
declined over time among patients with COVID-19 seeking hospital
care in the St. Louis area.
Regardless of these differences, many of the underlying cytokine
patterns were replicated between the primary and validation cohorts,
as most of the cytokine variation among the two COVID-19 cohorts
overlapped substantially (e.g., Fig. 4A and fig. S8, C and D). Yet, other patterns seemed not to replicate to statistical significance simply
due to a lack of power for the highly parameterized models required
to control for all demographic and clinical factors (20). This was not
particularly unexpected as the relatively high dimensionality of cytokine data and the tendency for extreme outliers can make it difficult
to detect statistically significant associations while conservatively
Mudd et al., Sci. Adv. 2020; 6 : eabe3024
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controlling for false discovery rate. To address this, we next sought
to integrate the cytokine data from the two COVID-19 cohorts by
using a data-driven modular informatics approach developed specifically for cytokine analyses (24). These analyses allowed us to detect
a number of co-correlating cytokines across COVID-19 samples,
which we grouped into distinct coexpression modules using hierarchical clustering (Fig. 4B). This unsupervised approach categorized
the 35 cytokines we assayed among COVID-19 samples into eight
distinct modules of cosignaling cytokines (fig. S8E), including a module
comprising HGF, IL-1RA, IL-6, and IL-8 (module 1; Fig. 4C). As
described above, most elements of this module were independently
found to be up-regulated in both influenza and COVID-19 groups
compared to healthy controls and were comparably expressed
between COVID-19 and influenza groups, save for IL-1RA, which
7 of 17
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Fig. 3. Selective cytokine up-regulation in COVID-19–infected patients from the validation cohort. (A) Left: PCA of all 35 cytokines measured in the COVID-19 validation cohort. Red circles represent samples with CSS cytokine profiles, blue dots represent samples with TH22 cytokine profiles, and green dots represent the remainder
of subjects. Samples with missing cytokine data were excluded. Right: The corresponding PCA loading plot, in which each cytokine has a vector/arrow which points in
the direction of increasing cytokine levels. The color and length of the vector represent how strongly each cytokine contributes to a principal component. (B to D) Box
plots show cytokine concentrations in healthy, influenza, primary COVID-19, validation COVID-19, primary CSS, validation CSS, and validation TH22 groups for all 35 cytokines measured, with raw values plotted on the log10 scale. Presented P values are from estimated marginal means (EMM) comparisons, averaging over all demographic
and clinical factors that were included as covariates and P values adjusted for multiple comparisons. Although TH22 samples were visualized separately, they were included as validation COVID-19 samples in the underlying statistical analyses. To the right of each box plot are EMM plots for the influenza–COVID-19 comparison; the black
dot represents the estimated marginal mean for the log10 concentration of the cytokine for a given condition, averaged over the levels of all other covariates (e.g., age,
sex, and ethnicity), and the blue shading represents the corresponding 95% confidence interval. The red arrows represent the SE in one direction, with overlapping SE
arrows indicating no significant difference between the EMM of a given cytokine in influenza subjects versus COVID-19 subjects.
Mudd et al., Sci. Adv. 2020; 6 : eabe3024
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Fig. 4. Cross-cohort comparisons. (A) Left: PCA of 35 cytokines measured across all patient groups in both primary and validation cohorts; all samples with complete
cytokine data were included in the analysis, but only the majority of sample variation is included in the visualization. Right: corresponding PCA loadings indicating effects
of each cytokine. (B) Correlations of log10 absolute cytokine values are visualized as the proportion of times cytokine pairs clustered together during hierarchical clustering over 1,000 permutations for all COVID-19 patients across cohorts. Colors alongside the dendrogram and cytokine names denote module membership, whereas colors
within the heatmap correspond to the ratio of coclustering. (C) Cytokine cocorrelations for all cytokines assigned to Module 1 (M1) are assessed using Pearson’s correlation coefficient. (D and E) Forest plots depicting the adjusted odds ratios obtained from multivariate logistic regression analysis between cytokines and various correlates
of COVID-19 disease severity. (D) Cytokine associations with ICU admission. (E) Cytokine associations with death. Logistic regression models used absolute log10-
transformed cytokine values and included age, sex, ethnicity, days since symptom onset at enrollment, all reported comorbidities, and cohort as covariates. Gray shading indicates the area of the plots where odds ratios are less than 1, indicative of negative associations. Adjusted odds ratios are indicated with points, and confidence lines
encompass the range between the lower and upper limits. Red indicates significance at false discovery rate < 0.1, † indicates that age was a significant covariate, and ‡
indicates that day of sampling after symptom onset was significant.
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Single-cell transcriptional profiles of COVID-19 subjects
with respiratory failure are concordant with signals
of targeted immunosuppression
Immune suppression can often occur as a negative feedback from
immune activation, so we sought further resolution of the immune
state of a subset of severe COVID-19 subjects to understand the
Mudd et al., Sci. Adv. 2020; 6 : eabe3024
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dominant regulatory signals determining their trajectory. A total of
37,469 cells from eight subjects (three COVID-19–infected, three
influenza-infected, and two healthy controls) were obtained for single-
cell gene expression analyses after standard processing and filtering.
All six of the infected subjects required intubation and mechanical
ventilation for severe respiratory failure, and ultimately three of the
COVID-19–infected patients and one of the three influenza-infected
patients died from their illnesses. Using an integration-based approach
that leverages convergent expression signals across samples (see
Materials and Methods), we identified 25 putative transcriptional
clusters that we were able to categorize into major cell subsets, including monocytes and macrophages (four transcriptional clusters
including CD16+ and CD16− monocytes), CD8+ T cells (three clusters
including putative naïve, effector, and central memory populations),
CD4+ T cells (two clusters including putative naïve and memory
populations), regulatory T cells (Tregs), innate-like T cells [including
gamma delta T cells and MAIT cells (mucosal-associated invariant
T cells)], B cells (two clusters including putative memory B cells),
plasmablasts, mixed cytolytic lymphocyte populations [MCLPs; four
clusters that potentially include natural killer (NK) and NKT cells],
platelets, red blood cells, granulocytes (putative), stromal cells, and
plasmacytoid dendritic cells (PDCs), as well as putative doublets
(Fig. 5A and fig. S9).
As variations in the relative abundance of subsets across groups
were obvious upon visual inspection (Fig. 5, A to C), we next interrogated each of these major groups and their constituent transcriptional clusters for variation in both relative abundance and gene
expression owed to differences in group (i.e., COVID-19–infected,
influenza-infected, or healthy control). Although some transcriptional
clusters had more cells from one condition or another (fig. S10), we used
an analytical approach that allowed us to detect differences between
conditions by simultaneously assessing the proportions of cells
expressing a gene and the expression of that gene within cells expressing it.
Given the substantial down-regulation of HLA-DR among COVID-19
monocytes observed during flow cytometry analysis, we decided to
further investigate potential transcriptional differences between
COVID-19 and influenza specifically within our transcriptionally
defined monocyte/macrophage subset and clusters. As expected, given
the flow cytometry analysis carried out on these same patients, the
proportion of cells in monocyte/macrophage clusters were substantially smaller in COVID-19 compared to both healthy and influenza
subjects (fig. S10). In addition, expression of the conserved class II
chain HLA-DR was significantly reduced in cells from patients with
COVID-19 compared to patients with influenza (Fig. 5D).
At the single-cell transcriptional level, many of the genes that we
profiled in our protein cytokine assays were rarely observed, likely due
to the sensitivity limitations of the gene expression kit. We therefore
used Gene Set Enrichment Analysis [GSEA; (26)] to broadly survey
transcriptional variation as a function of infection status in an unbiased
manner. Specifically, we ranked gene expression differences between
COVID-19–infected and influenza-infected patients for each subset
and tested for enrichment of Hallmark gene sets as a function of
these diagnoses. Unexpectedly, a number of important immunological
pathways were significantly enriched, specifically among cells from
patients with influenza across a number of subsets: Compared to
the influenza condition, both IFN- and IFN- response pathways
were significantly down-regulated within the COVID-19 condition
for B cells, plasmablasts, CD8+ T cells, MCLPs, Tregs, PDCs, and
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showed decreased expression among COVID-19 subjects compared
to influenza subjects. Plasma IL-6 and IL-8 have been shown to
correlate strongly in large pediatric and adult influenza cohorts,
albeit typically with G-CSF and MIP-1 as well (24); in contrast,
among COVID-19 samples, G-CSF clustered with IL-1, IL-9, and
TNF (module 3), whereas MIP-1 clustered with 13 other cytokines, including several ILs and IFN- (module 5). Module 5 contained cytokines associated with type 1 (IL-12), type 2 (IL-4), and
type 3 (IL-17f) immune responses, including those secreted by innate (IFN- and IL-1) and adaptive (IL-4 and IL-15) immune cells.
Notably, several cytokines were assigned to their own modules due
to a lack of sufficient correlation with others, including the chemokine
RANTES (module 8), vascular endothelial growth factor (VEGF;
module 2), and IFN- (module 7). In general, these analyses suggest
that aspects of typical cytokine cosignaling modules inferred from
large cohorts in other severe respiratory diseases are altered in
the context of COVID-19, indicative of a unique immunoregulatory
environment in COVID-19 potentially demonstrated by the overall
reduced inflammatory profile. The significantly lower levels of IFN-
and its lack of clustering with other cytokines suggests that this prototypical type 1 cytokine is not being produced in a manner typical
of other common viral infections.
Using this analytical framework further, we next inquired whether
particular cosignaling modules or individual cytokine expression
patterns were associated with clinical outcomes among patients with
COVID-19. Here, we used multivariate logistic regression, again
controlling for age, sex, ethnicity, days since symptom onset at
enrollment, and all reported comorbidities to calculate adjusted
odds ratios of severity. Because these analyses spanned both primary
and validation cohorts, we also included cohort as a covariate to
control for any potential cryptic differences between the patient
populations, and we adjusted for multiple comparisons (13 covariates
tested within each model) by controlling the false discovery rate.
These analyses revealed a number of significant associations between
various measures of disease severity, cosignaling cytokine modules,
and their constituent cytokines. For instance, increases in cytokine
modules 1, 2, and 6 were associated with increased odds of requiring
ICU admission, as were HGF, IL-1RA, IL-6, IL-8, VEGF, G-CSF,
IL-15, IL-1, MCP1, MIP-1, and MIG individually (Fig. 4D). Increases in module 1 and most of its constituent cytokines, as well as
G-CSF and IL-1, were likewise associated with increased risk of
death (Fig. 4E). While some of these cytokines (IL-6 and IL-8) have
been implicated previously in COVID-19 pathogenesis, our comprehensive screening approach has identified a signature that is
notable for its focus on largely innate inflammatory mediators associated with monocyte and neutrophil mobilization. In addition, in
our analysis, there was a lack of association with traditional adaptive inflammatory markers (IFN-, IL-13, and IL-5) that has been
observed in some other reports (25). Strikingly, this severity signature
is reminiscent of the innate monocyte mobilization signature identified in patients with influenza using a similar statistical approach,
with the notable lack of IFN- associations (20, 24).
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Fig. 5. Single-cell gene expression analyses of PBMCs from COVID-19–infected, influenza-infected, and healthy participants demonstrate profound differences
in the relative abundance and transcriptional activity of cell subsets across conditions. (A) Uniform Manifold Approximation and Projection (UMAP) plots depict
transcriptional clusters, which (B) vary transcriptionally as a function of condition despite the presence of nearly all subsets across various conditions, as evidenced in (C).
(D) Violin plots demonstrate significant down-regulation of HLA-DRA among all cells from COVID-19–infected patients compared to influenza-infected patients (with
healthy controls included for reference). Asterisks indicate significance at Bonferroni-corrected P values < 0.001. (E) GSEA analysis of gene expression differences between
COVID-19 and influenza groups across major cell subsets. In direct comparison to cells from influenza-infected patients, transcriptional patterns among cells from
COVID-19–infected patients reveal significant up-regulation (red bars) of metabolic pathways, stress pathways, and glucocorticoid signaling pathways across major cell
subsets, particularly monocytes/macrophages. In contrast, interferon pathways were significantly down-regulated (blue bars) among subsets from COVID-19–infected
patients compared to those from influenza-infected patients. Gray bars indicate that tests for enrichment did not meet statistical significance for a particular subset.
(F) Violin plots demonstrate significant down-regulation of STAT1, STAT2, and STAT3 among monocytes/macrophages from COVID-19–infected patients compared to
influenza-infected patients (with healthy controls included for reference). Asterisks (***) indicate significance at Bonferroni-corrected P values of <0.001.
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DISCUSSION

Understanding the complexities of the systemic inflammatory response to SARS-CoV-2 infection is critical to determining the most
appropriate treatment for this condition. We have demonstrated
that the immunophenotypes of COVID-19 and influenza patients
vary widely. Multiple forms of COVID-19 immune dysregulation
were observed: a cytokine storm phenotype in 3 to 4% of patients
across primary and validation cohorts (7 of 168), a TH22 phenotype
in 3% of the validation cohort patients (3 of 89), and a far more
common phenotype characterized by targeted immunosuppression
relative to influenza-infected patients. The signatures of this common COVID-19 phenotype compared to influenza were equivalent
levels of IL-6 and IL-8, paired with lower levels of cytokines in many
other pathways and essentially the absence of any type I or type II
IFN response. The suppression in type I IFN signaling has been noted by others in humans and animal models of COVID-19 infections
(27–29). At the cellular level, marked reductions in overall cellularity,
particularly in the monocyte compartment, were observed, with
phenotypic and transcriptional evidence that monocytes were less
activated. While lymphocyte numbers (except for plasmablasts) were
reduced in both infected groups compared to healthy controls, several lymphocyte subsets had functional signatures of suppression in
patients with COVID-19 compared to patients with influenza, inMudd et al., Sci. Adv. 2020; 6 : eabe3024

9 December 2020

cluding type I and II IFN signaling. IFN- production is critical for
effector type I responses, and its absence may limit antiviral activity.
The elevated plasmablast frequencies in COVID-19 patients may
reflect the abundance of viral antigens, which is consistent with the
reported persistence of viral RNA in nasal swabs for up to 15 days
after onset of symptoms (30).
The single-cell analyses also identified enrichment of several
pathways in COVID-19–infected patients associated with metabolic
stress and the general stress response. These results, combined with
the targeted, severe suppression of specific pathways and marked
leuko- and lymphopenia, led us to consider what pathways might
account for this response profile. Previous studies in animal models
had implicated glucocorticoid (GC) signaling in the immunosuppression and lymphopenia that occurs in the influenza model in mice
(31). In humans, systemic inflammation and hydrocortisone, specifically, are known to suppress HLA-DR expression on monocytes (32).
Excessive GC production is an attractive hypothesis to account
for the observed immune dysregulation and disease manifestations
in COVID-19. First, the relatively high levels of IL-6 production can
directly drive excessive cortisol production through multiple mechanisms, including through the direct induction of corticotropin-
releasing hormone and adrenocorticotropin. IL-6 can also act
directly on the adrenal cortex to stimulate GC release (33). While GCs
are generally immunosuppressive, which is why they are often used
therapeutically, their effects are uneven across the cytokine landscape, with cortisol failing to suppress IL-6 (34) or even inducing
IL-6 and IL-8 in one report (35). A recent retrospective cohort study
from Germany has also reported increased cortisol levels in a
majority of patients with COVID-19 (36), while another analysis
found an association between risk of COVID-19 mortality and high
levels of serum cortisol (37).
A recent report from the RECOVERY trial has suggested that, in
contrast to this hypothesis, treatment with steroids (dexamethasone)
had a significant protective effect in reducing mortality among the
most severe COVID-19 patients (8). These data demonstrated a statistically significant reduction in mortality among patients requiring
oxygen (21 versus 25%) or ventilation (29 versus 40%). In light of
our findings, we would hypothesize that this subset of patients that
was aided (~5 to 11% of the most severe patients and approximately
2% of the total cohort of COVID-19 patients enrolled in the study)
represented those who had the severe cytokine storm immunotype.
Intriguingly, in those patients not receiving respiratory support,
outcomes for patients on dexamethasone were poorer, with 17%
mortality versus 13.2% in the control group (although this was not
statistically significant; P = 0.14). Other reports have similarly found
deleterious effects of GC administration in COVID-19 and related
illnesses (38). On the basis of our results, we might hypothesize that
this lack of efficacy in this larger population may correspond to patients already experiencing higher levels of GC production. This
hypothesis would need further verification, with direct measurement of GCs. If confirmed, therapeutic consideration should be given
to inhibiting both IL-6 and GC activity in most of the patients with
COVID-19 exhibiting this phenotype (high IL-6, low IFN signaling,
and profound cytopenias) versus the small proportion of patients
with a true cytokine storm phenotype. A focus on understanding
GC dynamics and activity across the course of infection is an important direction for future research.
Cytokine storms were originally defined in graft versus host disease
manifestations of hematopoietic stem cell transplants (39). Subsequent
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monocyte/macrophage subsets (Fig. 5E and fig. S11). These pathway-
based analyses were particularly informative, as there was no significant
difference in expression of IFN- itself in these subsets, and we were
unable to detect IFN- transcripts at all. More exhaustive analysis
using gene ontology pathways related to interferon production,
secretion, response, and regulation demonstrated that patterns observed among IFN- and IFN- pathways extended to IFN- (which
was also not directly detected in the transcriptomic data) and general
type I interferon pathways across most subsets but particularly
among monocytes (fig. S11). These patterns were concordant with
substantial enrichment of inflammatory pathways in influenza cells
compared to COVID-19 cells across a majority of cell subsets. In
contrast, COVID-19 cells were significantly enriched for a number
of pathways involved in cellular metabolism, stress, corticosteroid
stimulus, and proliferation in comparison to influenza cells across
most subsets (Fig. 5E and figs. S12 and S13).
To confirm these observations, we looked at the specific expression of Stat genes, including the IFN-associated signal transducers
and activators of transcription 1 (STAT1) and STAT2, which were
both significantly underrepresented in patients with COVID-19 compared to patients with influenza (Fig. 5F). STAT3, which is critical
for IL-6 signaling, was also expressed significantly less in patients
with COVID-19 compared to patients with influenza despite the
elevated levels of IL-6 circulating in these subjects. Together, these
data indicate that, in this subset of patients with COVID-19, there
was a general refractoriness to certain inflammatory signals, including IFNs. Although the transcriptional signals from this subset of
patients were concordant with the robust phenotypic patterns observed across our much larger cohorts, it is important to note that
others have reported dissimilar findings in their own transcriptional
comparisons of treated influenza-infected and COVID-19–infected
patients (15). Future work, as discussed below, will be important for
fully understanding the diverse biological and immunological patterns underlying these heterogenous patient populations.
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differences between these two viral infections; this may include the
duration of the presymptomatic period of infection. The time course
of the immune response to these two distinct viral pathogens is likely
not identical despite our efforts to provide statistical correction
for these variations. Last, our study does not include a truly mild
COVID-19 group, such as asymptomatic patients. This group is
particularly hard to enroll and sample in the current setting as they
are requested to avoid the clinic, and it is important to note that our
conclusions do not necessarily generalize to these milder infections.
MATERIALS AND METHODS

Study design
This is a prospective observational cohort of subjects with viral
respiratory illness symptoms who presented to Barnes Jewish Hospital,
St. Louis Children’s Hospital, Missouri Baptist Medical Center or
affiliated Barnes Jewish Hospital testing sites located in Saint Louis,
Missouri, USA. Inclusion criteria required that subjects were symptomatic and had a physician-ordered SARS-CoV-2 test performed
in the course of their normal clinical care. Some subjects were enrolled before the return of the SARS-CoV-2 test result. Enrolled subjects who tested negative for SARS-CoV-2 are not included in the
current manuscript. This report includes the first subjects enrolled
in the study. The first 79 SARS-CoV-2+ subjects compose our primary cohort and the next 89 enrolled SARS-CoV-2+ subjects make
up the validation cohort. Study recruitment is ongoing. All samples
were collected at the time of enrollment, and there was a median
interval between hospital admission and enrollment of 1 day (which
corresponded to the median turn-around time for the SARS-CoV-2
clinical reverse transcription PCR test). Patient-reported duration
of illness and other clinically relevant medical information was
collected at the time of enrollment from the subject, their legally
authorized representative, or the medical record. The vast majority
of samples from patients testing positive for SARS-CoV-2 were collected immediately after the treatment team learned that the subjects
were positive, and therefore, most patients will not have received
any specific treatment before sample collected. We obtained less
information about whether treatment had begun before sample
collection for the validation cohort, hence, the consideration of the
primary and validation cohorts separately throughout the majority
of the manuscript. The portions of the study relevant to each institution were reviewed and approved by the Washington University
in Saint Louis Institutional Review Board (WU-350 study approval
no. 202003085) and the Missouri Baptist Medical Center Institutional
Review Board (approval no. 1132). The study complied with the
ethical standards of the Helsinki Declaration.
We also report findings from healthy control subjects and influenza-
infected subjects enrolled in separate, ongoing studies. Control subjects had not experienced symptoms of a viral respiratory illness at
the time of sample collection or within the previous 90 days, and
samples were all collected before October of 2019. Influenza subjects were enrolled in the ongoing EDFLU study (45). All influenza
subjects were sampled in 2019 and 2020. We enrolled most influenza
subjects during the course of the 2019 to 2020 influenza season, immediately before the spread of COVID-19 disease in the Saint Louis
region. The last included influenza subject was enrolled and sampled
on 2 March 2020. The first case of COVID-19 was reported in Saint
Louis on 8 March 2020 in a returning traveler. The control and
influenza studies were independently approved by the Washington
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characterization of extraordinary levels of cytokines in H5N1 avian
flu infections in vitro and in vivo led to an exploration of this
phenotype in infection models (40). In general, seasonal influenza infections such as those studied here, even fatal cases were not associated with this phenotype, while the emergence of a previously
unknown avian influenza virus (H7N9) again demonstrated a hypercytokinemia phenotype (41). Recent literature has started conflating
“cytokine storms” with generally, but not exceptionally, elevated cytokine levels. We have tried to emphasize here that regardless of the
terminology, this small but significant subgroup of patients with outlier levels of many cytokines needs special consideration and is most
consistent with the “cytokine storm” literature (11, 13, 42). For instance,
one patient with CSS had 1,080,000 pg/ml IL17f, whereas the
average value among all patients with non-CSS COVID-19 is
1435 pg/ml.
Our findings are consistent with severe COVID-19 disease resulting from diverse underlying immunological profiles. While a
subset of patients exhibit the cytokine storm phenotype, the majority
do not, including most of those who progress to the severest outcomes.
Another study using cell-based immune profiling also identified
diverse “immunotypes” associated with varying outcomes, including
strong activation and expansion in adaptive immune compartments
(T cells and plasmablasts) in some patients, while other patients appeared to have no measurable adaptive immune activation above
baseline (43). We attempted to define the cytokine storm subset
using commonly measured clinical parameters (e.g., C-reactive protein levels), or combinations thereof, but thus far have not identified
a statistically informative predictor. Other groups analyzing severe
COVID-19 cohorts have similarly failed to directly correlate clinically measured parameters in patients with cytokine storm phenotypes (44). Ideally, parsing the diverse and therapeutically distinct
immune profiles underlying severe COVID could be assessed with
a simple, fast, inexpensive, robust test; a minimal set of cytokines
(e.g., simultaneous assessment of some combination of EGF, FGF,
IL-15, MIP-1, IL-3, and/or other cytokines with consistent outliers
in figs. S2 and S5) may currently be the most tractable option.
There are several important limitations to the current work,
including our focus on the circulating peripheral blood compartment.
At the initiation of the study, the safe collection of respiratory samples
from patients with COVID-19 had not been established, although
we plan to address the local features of inflammation in subsequent
reports, including addressing whether some of the peripherally depleted subsets may have migrated to the inflamed airways. Ideally,
longitudinal samples would also be used to determine the trajectory
of each immune profile to determine their stability. In addition, we
focused on the first blood sample collected from each subject,
which, in more than 75% of enrolled subjects, was collected from
the patient at the same time that the treating team learned of the
patient’s COVID-19 diagnosis. Although limiting the possibility that
substantial disease-specific therapeutic interventions were used before initial sample collection removed a major potential source of
variation among our subjects, in future studies, it will be critical to
understand how the array of therapeutic modalities currently being
applied affect our identified immune profiles. Furthermore, our
study compares initial enrollment blood samples from COVID-19
subjects and acute influenza subjects. While there was no significant
difference between the duration of symptoms before sample collection
between the two groups and multivariate analyses used throughout
our manuscript controlled for duration of symptoms, there remain
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201801209, 201808171, 201710220, 201808115, and 201910011).

Cytokine quantification
Plasma obtained from subjects was frozen at −80°C and subsequently
analyzed using a human magnetic cytokine panel providing parallel
measurement of 35 cytokines (Thermo Fisher Scientific). The assay
was performed according to the manufacturer’s instructions with
each subject sample performed in duplicate and then analyzed on a
Luminex FLEXMAP 3D instrument.
Single-cell RNA sequencing
PBMCs were suspended at 1000 cells/l, and approximately 17,400
cells were input to a 10× Genomics Chromium instrument. Aside
from healthy control sample ZW-WU321, each sample was used for
two independent reactions, with all first reactions processed on one
chip and second reactions processed on a second chip. Single-cell
gene expression libraries were prepared using 5′ (V2) kits and
sequenced on the Illumina NovaSeq 6000 platform at 151 × 151 base
pair. Individual libraries were processed using CellRanger (v3.1.0;
10× Genomics) with the accompanying human reference (GRCh38
3.0.0), which was modified to include the influenza A, influenza B,
and COVID-19 (NC_045512.2) genomes. Processed libraries were
subsequently aggregated using CellRanger, randomly subsampling
mapped reads to equalize sequencing depth across cells. Filtered
aggregation matrices were subsequently analyzed using Seurat (46)
(v3.2.0), excluding cells from downstream analyses that exhibited
extremes in the total number of transcripts expressed, the total
number of genes expressed, or mitochondrial gene expression. For each
cell, we inferred cell cycle phase using markers from Tirosh et al.
(47) and incorporated module scores from a number of external gene
sets in the same manner.
After filtering, we first sought to characterize putative cell subsets shared across conditions by detecting integration anchors among
the samples, effectively minimizing condition-associated differences.
The top 2000 variable genes were identified for each library using the
“vst” method, and integration anchors were obtained using canonical
correlation analysis (CCA). Data were integrated using 50 CCA dimensions and scaled to regress out the effects of total transcript count,
percent of mitochondrial gene expression, and module scores associated
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Data availability
Raw flow cytometry and cytokine data can be found in table S1.
Single-cell gene expression data have been uploaded to the National
Center for Biotechnology Information (NCBI) Short Read Archive
under BioProject ID PRJNA630932 and SRA accession SRR11233662.
Analysis
Cohort comparisons
Statistical analyses of primary cohort demographics included pairwise comparisons between COVID-19 and healthy groups for age,
sex, and ethnicity using a multinomial logistic regression, with the
variation from the influenza group included in the model. Results
were reported as odds ratio and (when significant) corresponding
P value. Comparisons between COVID-19 and influenza groups
were performed using a multivariate logistic regression between the
COVID-19 and influenza groups only, as the clinical variables were
irrelevant to healthy controls. The “immunocompromised” comorbidity was not included in the primary cohort logistic regression
because it perfectly segregated across groups. The COVID-19 validation cohort was compared to the COVID-19, healthy, and influenza
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Multi-parameter flow cytometry
Absolute counts of CD45+ cells in whole blood were determined at
the time of blood collection on fresh samples by flow cytometry
with Precision Count Beads (BioLegend). PBMCs, prepared using
ficoll separation, were analyzed using a panel of antibodies directed
against the following antigens: CD8 BV421 (clone RPA-T8), CD20
Pacific Blue (clone 2H7), CD16 BV570 (clone 3G8), HLA-DR BV605
(clone L243), immunoglobulin D (IgD) SuperBright 702 (clone IA6-2),
CD19 BV750 (clone HIB19), CD45 Alexa Fluor 532 (clone HI30),
CD71 PE (clone CY1G4), CD38 PE-Cy7 (clone HIT2), CD14 APC
(clone M5E2), CD4 Spark 685 (clone SK3), and CD3 Alexa 700
(clone UCHT1). PBMC samples of 0.5 to 2 × 106 cells were stained
with a master-mix containing pretitrated concentrations of the antibodies, along with BD Brilliant Buffer (BD Biosciences) and Zombie
NIR Fixable Viability Marker (BioLegend) to differentiate live and
dead cells. Samples were run on a Cytek Aurora spectral flow cytometer using SpectroFlo software (Cytek) and unmixed before final
analysis was completed using FlowJo software (BD Biosciences).

with cell phase. Principal components (PC) were calculated and assessed for statistical significance using random permutation. The
first 45 PCs (P < 0.01) were used to identify transcriptional clusters and
for t-distributed stochastic neighbor embedding and UMAP (uniform
manifold approximation and projection) dimensionality reduction.
After identifying clusters on the basis of transcriptional similarities
across cells from all three conditions (i.e., the “integrated” analysis),
we performed pairwise differential gene expression analysis between conditions using Wilcoxon rank sum tests as implemented
in Seurat, with default parameters. We also generated an additional
UMAP projection using the top 2000 variable genes across the entire
dataset (excluding T cell receptor and immunoglobulin (IG) genes,
which are known to map poorly) irrespective of the CCA but again
using significant PCs; this allowed us to visualize cells in a manner that
did not obscure transcriptional differences owed to sample or condition but with previously identified cell subsets and transcriptional
clusters from the integration analysis overlaid. We also looked within
identified subsets and clusters for explicit differences in gene pathway enrichment between cells from COVID-19–infected and
influenza-infected patients, COVID-19–infected and healthy participants, and influenza-infected and healthy participants. For these
analyses, gene expression differences between conditions were ranked
for individual subsets and transcriptional clusters by calculating differential expression under a generalized linear hurdle model (48).
To generate gene ranks, gene-specific average log fold changes were
multiplied by the absolute difference in the proportions of cells expressing the gene (1 × 10−4 as a lower boundary) and the inverse of the
Bonferroni-corrected P values, which were rescaled from 1 × 10−7 to
1 to institute reasonable bounds in the ranking; this approach has
been implemented previously (49) to synthesize information about
average expression differences, the fraction of cells expressing the
gene at all, and statistical assessments of significance. These ranks
were used as inputs for gene set enrichment analysis (26) using GSEA
Preranked with a classic enrichment statistic and chip-based gene collapsing on the basis of the Human_Symbol_with_Remapping_
MSigDB.v.7.0 chip (50). Gene sets were considered significantly
enriched if they resulted in a nominal P value of <0.05 and a q value
of <0.20.
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